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Objective: A previous study established that interstitial cystitis/bladder pain syndrome (IC/BPS) patients
had signiﬁcantly more dyspareunia and fear of pain than healthy controls. We evaluated the relation-
ships between lower urinary tract symptoms and dyspareunia in IC/BPS patients.
Materials and methods: A total of 156 IC/BPS female patients were included in this study. The diagnosis
was made on the consensus of IC/PBS proposed by the Society for Urodynamics and Female Urology
criteria in 2008. All women completed measures of pain severity (visual analog scale) and bladder
symptom severity [IC Symptom Index, IC Problem Index, and the Pelvic Pain and Urinary/Frequency
(PUF) scale]. Respondents were asked to recall if they experienced any sexual pain during or after sexual
intercourse in the past 1 year. Cystoscopic hydrodistension during general anesthesia was performed for
5 minutes and maximal bladder capacity was also measured. Bivariate analyses were performed using
chi-square and independent Student t tests.
Results: Of the women with a current sexual partner, 61% (96/156) reported dyspareunia during or after
sexual intercourse. Of the 96 dyspareunia respondents, 46% (44/96) reported pain in the bladder only,
43% (41/96) in the vagina only, and 11% (11/96) in both the bladder and the vagina. Patients with dys-
pareunia complained of more severe urological pain (p ¼ 0.02), a higher PUF scale score (p < 0.01), and
larger anesthetic maximal bladder capacity (p ¼ 0.04) than patients without dyspareunia. However,
patients with dyspareunia at the bladder only had more severe urgency sensation (p < 0.01) but no
differences in pain, PUF scale, severity of glomerulation, and maximal bladder capacity than those with
dyspareunia at the vagina only.
Conclusion: IC/BPS women with dyspareunia have signiﬁcantly more severe urological pain and a higher
PUF scale score than women without dyspareunia. Physicians should consider sexual pain disorder in the
management of patients with IC/BPS and use the PUF scale to evaluate not only IC-speciﬁc lower urinary
tract symptoms, but also sexual pain disorder.
Copyright © 2015, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic
disease characterized by a constellation of symptoms, including
pelvic pain, pressure, and discomfort perceived to be related to the
bladder with frequency, persistent urge, or nocturia in the absenceYuan Hospital, Department of
rict, Taichung 42055, Taiwan,
.
ociation. Published by Elsevier Taof bacterial infection or other identiﬁed pathologic disease. The
prevalence of IC/BPS, as reported by the Rand Interstitial Cystitis
Epidemiology study, was estimated to be 2.70e6.53% in the United
States.1
Dyspareunia is deﬁned as pain experienced during or after
sexual intercourse, and may be due to an organic and/or psycho-
logical cause.2 IC/BPS, a potential cause of sexual pain in women,
should be considered in the differential diagnosis for dyspareunia
because it is estimated to occur in 49e90% of women with IC/BPS.3
In a recent caseecontrol study comparing 215 patients with IC/
BPS to 823 controls, Peters et al4 reported more dyspareunia, moreiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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women with IC/BPS than in healthy controls. Another study also
revealed that womenwith IC/BPS symptoms experienced very high
levels of sexual dysfunction.5 Moreover, IC/BPS patients are resis-
tance to penetration due to fear of pain. The reason why sexual
intercourse may exacerbate the symptoms is that penetration can
cause more pain and mechanical trauma to the vestibule and ure-
thra, and can exacerbate urological and pain symptoms of IC/BPS.6
Recently, Nickel et al7 reported the UPOINT (Urinary, psycho-
social, organ speciﬁc, infection, neurogenic/systemic, tenderness)
phenotyping system can classify patients with IC/BPS according to
clinically relevant domains. Being included in the tenderness
domain predicted more severe general symptoms measured by the
IC Symptom Index (ICSI) and the Pelvic Pain and Urinary/Frequency
(PUF) scale, as well as urgency. We proposed that patients diag-
nosed of IC/BPS with the presence of dyspareunia could be a spe-
ciﬁc phenotype and compared as a separate group with a pure IC/
BPS without presence of dyspareunia.
The purpose of this study is to examine the relationships be-
tween lower urinary tract symptoms including the symptom pro-
ﬁle, using validated questionnaires, duration of symptoms,
anesthetic maximal bladder capacity (MBC), severity of glomer-
ulation, and dyspareunia in IC/BPS patients.
2. Materials and methods
2.1. Patients
This is a retrospective cross-sectional study. The study included
156 female patients with a diagnosis of IC/BPS from January 2009 to
February 2014. The diagnosis was made on the consensus of IC/BPS
proposed by the Society for Urodynamics and Female Urology
criteria in 2008. All patients were diagnosed on the basis of chronic
(> 6 weeks) pelvic pain, pressure, or discomfort perceived to be
related to the urinary bladder accompanied by at least one other
urinary symptom, such as frequency, persist urge, or nocturia, in
the absence of infection or other identiﬁable causes.8 All other
confusable diseases including neurogenic bladder, urolithiasis, and
chronic urinary tract infection that could cause pelvic symptoms
were excluded by standardized history and physical examination.
Cystoscopic hydrodistension was performed using general anes-
thesia to rule out any other confusable disease such as carcinoma in
situ and also to provide a temporal therapeutic effect. Although
glomerulations were not a requirement for the diagnosis of IC/BPS,
all of the patients had different degrees of glomerulations instead of
classical Hunner's ulcer.
2.2. Measures
All patients were asked to provide information on their age, IC/
BPS symptom onset, and education level, and to recall if they
experienced sexual pain during or after sexual intercourse in the
past year. All the respondents had engaged in vaginal sex in the past
year. There were two questions for dyspareunia history: (1) “Do you
feel pain during or after sexual intercourse?” and (2) “At which site
was the pain located (bladder, vagina, or both)?”. Urogenital pro-
lapse, vaginal candidiasis, and cervical, uterine, and ovarian cancers
were excluded.
All IC/BPS women completed a symptomatic questionnaire: (1)
IC/BPS symptoms, including frequency, urgency, nocturia, and pain,
were assessed using the O'LearyeSant Questionnaire as ICSI and IC
Problem Index (ICPI).9 The PUF scale was also completed, which
assessed both pelvic pain and urinary symptoms, as well as pain
associated with sexual activity.10 (2) Pain and urgency were
assessed by visual analog pain and urgency scales (VAS-pain andVAS-urgency), with scores ranging from 0 (no symptom) to 10 (the
worse symptom imaginable).
Cystoscopic hydrodistension was applied under general anes-
thesia, and the bladder was distended to the maximal capacity for 5
minutes with a pressure of 80e100 cmH2O. During cystoscopic
hydrodistension, anesthetic MBC was measured. Severity of glo-
merulationwas classiﬁed, according to the ESSIC (European Society
for the Study of Interstitial Cystitis/Painful Bladder Syndrome)
classiﬁcation, as Grades 1e4.11
2.3. Statistical analysis
One-way analysis of variance was used in patients positive or
negative for sexual pain and pain in the bladder or vagina. We used
Chi-square tests to evaluate the associations between dyspareunia
condition (presence or absence) and severity of glomerulation.
Signiﬁcance was set at p  0.05. The analyses were performed with
SPSS version 21.0 software (SPSS Inc., Chicago, IL, USA).
3. Results
The questionnaire survey was completed by 156 patients. The
mean age of the patients with IC/PBS in this study was 43.8 ± 12.6
years, with a mean symptom duration of 8.0 ± 8.2 years (range 1e38
years). For ICSI, ICPI, and PUF the average scores were 13.1 ± 3.4,
11.8 ± 3.1, and 19.8 ± 5.9, respectively. The mean VAS-pain and VAS-
urgency scoreswere 5.3± 2.9 and 6.6± 2.2, respectively. The average
MBC was 696.8 ± 213.8 mL. Severity of glomerulation was classiﬁed
according to the ESSIC classiﬁcation as Grade 1.
Of all women with a current sexual partner, 61% (96/156) re-
ported dyspareunia during or after sexual intercourse. Of the 96
respondents with dyspareunia, 46% (44/96) reported pain in the
bladder only, 43% (41/96) in the vagina only, and 11% (11/96) in both
the bladder and the vagina (Fig. 1).
Table 1 shows various measures between women positive or
negative for sexual pain, which were analyzed using one-way
analysis of variance. There was a signiﬁcant difference in pain
severity, PUF scale score, and MBC reported by patients with
dyspareunia versus those without dyspareunia. Table 2 lists pa-
tients with dyspareunia at the bladder only who reported more
severe urgency (p ¼ 0.03) and larger MBC (p ¼ 0.04) compared to
those without dyspareunia. Table 3 shows that when examining
patients with dyspareunia at the vagina only versus those without
dyspareunia, no difference was found in bladder symptom and
MBC. There were no differences in symptomatic severity and MBC
between patients with dyspareunia at the bladder and those at the
vagina.
There were no differences in the severity of glomerulation be-
tween patients positive and negative for dyspareunia (p ¼ 0.18).
Moreover, dyspareunia at the vagina only and that at the bladder
only showed no differences in severity of glomerulation (p ¼ 0.23,
vagina only; p ¼ 0.24, bladder only).
4. Discussion
Dyspareunia is a common symptom among patients with IC/
BPS. The most frequent association between IC/BPS and dyspar-
eunia is pelvic ﬂoor dysfunction. Many patients with IC/BPS have
concurrent pelvic ﬂoor dysfunction, including symptoms such as
muscle tenderness and spasms. It has been reported that the
prevalence of pelvic ﬂoor dysfunction in patients with IC/BPS
ranged from 50% to 87%.12
In our data, about 60% of IC/BPS patients complained of dys-
pareunia. Patients with dyspareunia have severe suprapubic pain,
but not lower urinary tract symptoms, compared with patients
Fig. 1. Prevalence of dyspareunia and pain in the bladder and the vagina.
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found in patients with dyspareunia. Sub-PUF score analysis
showed that the reason why the PUF score is higher in patients
positive for dyspareunia is according to higher sexual pain score
and suprapubic pain score. It implied that patients with dyspar-
eunia seemed to belong to the severe group andmight have a poor
quality of life.
A subgroup analysis was carried out according to the area of
dyspareunia. We observed that IC/BPS patients always complained
of two types of dyspareunia, pain in the vagina and bladder irri-
tation. No difference was observed in symptom severity between
patients with dyspareunia restricted to a gynecological organ (va-
gina) and those without dyspareunia. The reason why dyspareunia
is restricted to the vagina is unclear. It can be reasoned that the
urinary and reproductive systems are embryologically related, and
“cross-talk” conditions that affect one system may also affect the
other.6 A recent study reported that 93% of women seeking care in a
gynecological pelvic pain clinic have some urinary symptoms as
well.13 Dyspareunia restricted to vagina may be one of subgroups of
IC/BPS patients from a gynecological cause or distinct entities
entirely with similar symptoms.
However, IC/BPS patients with dyspareunia radiated to the uri-
nary system (bladder) show more severe lower urinary tract
symptoms (urgency). One possible reason may be that mechanical
irritation of the bladder during intercourse may cause discomfort,
and repeated trauma can exacerbate symptoms of IC/BPS.14 A recent
study by Professor Nickel and coworkers,7 with regard to differenceTable 1
Differences between severity of symptoms measured by VAS-pain scale, urgency,
ICSI, ICPI, and PUF scale, and the presence or absence of dyspareunia using one-way






Age (y) 45.51 ± 12.9 42.11 ± 12.0 0.06
Symptom
duration
8.40 ± 7.8 8.01 ± 8.6 0.83
ICSI 13.03 ± 3.3 13.21 ± 3.5 0.76
ICPI 11.75 ± 2.9 11.82 ± 3.2 0.88
VAS-pain 4.56 ± 3.3 5.76 ± 2.5 0.01*
VAS-urgency 6.38 ± 2.1 6.81 ± 2.3 0.27
PUF 18.18 ± 5.5 20.69 ± 5.8 0.009*
MBC 654.25 ± 205.3 724.11 ± 214.6 0.04*
Glomerulations
Grade 1 4 (6.6) 4 (4.1) 0.18
Grade 2 15 (25) 15 (15.6)
Grade 3 16 (26.6) 29 (30.2)
Grade 4 25 (41.6) 48 (50.0)
Data are presented as n (%) or mean ± SD.
*p < 0.05.
ANOVA ¼ analysis of variance; ICPI¼ Interstitial Cystitis Problem Index;
ICSI ¼ Interstitial Cystitis Symptom Index; MBC ¼ maximal bladder capacity;
PUF ¼ pelvic pain and urinary/frequency; VAS ¼ visual analog scale.of symptom severity based on UPOINT classiﬁcation, revealed that
patients positive for tenderness domain had more severe bladder
symptoms compared to negative patients (VAS-urgency and ICSI, as
well as the PUF scale), but no difference was observed in the VAS-
pain score. Dyspareunia radiated to the bladder may be a potential
progressive phenotype of these IC/BPS patients.
Interestingly, our results indicate that IC/BPS patients with
dyspareunia radiated to the bladder had larger MBC than those
without dyspareunia. Moreover, there is no difference in severity
of glomerulation, which means that the differences in MBC were
not mainly caused by severity of glomerulation. In a recent study,
Colaco et al15 reported that IC/BPS patients with small bladder
capacity (MBC < 400mL) showed a different gene expression from
IC/BPS patients with normal capacity and healthy control groups.
IC/BPS patients with dyspareunia radiated to the bladder have
larger bladder capacity but severe lower urinary tract symptoms
(urgency score), which imply that the underlying etiology may
differ between patients negative for dyspareunia and those with
dyspareunia radiated to the bladder. The IC/BPS patients with
dyspareunia might be a speciﬁc phenotype compared with a pure
IC/BPS without the presence of dyspareunia. Further basic
research is required in order to examine the possibility of further
phenotyping.
Treatment of IC/BPS patients with dyspareunia is multimodal
and challenging due to various causes, in addition to overlapping
biological, psychological, and interpersonal etiologies.16 A recent
study showed that a reduction in IC/BPS symptoms has a positive
impact on sexual functioning.17 Therapy should be focused on
suprapubic pain, a landmarked symptom of IC/BPS, includingTable 2
Comparison of patients negative for dyspareunia and those with pain in the bladder






Age (y) 45.51 ± 12.9 40.04 ± 10.3 0.07
Symptom
duration
8.40 ± 7.8 8.45 ± 8.7 0.99
ICSI 13.03 ± 3.3 13.88 ± 3.3 0.48
ICPI 11.75 ± 2.9 12.14 ± 3.0 0.87
VAS-pain 4.56 ± 3.3 5.93 ± 2.5 0.08
VAS-urgency 6.38 ± 2.1 7.56 ± 2.0 0.03*
PUF 18.18 ± 5.5 20.60 ± 5.5 0.10
MBC 654.25 ± 205.3 753.88 ± 230.6 0.04*
Glomerulations
Grade 1 4 (6.6) 3 (6.8) 0.24
Grade 2 15 (25) 6 (13.6)
Grade 3 16 (26.6) 17 (38.6)
Grade 4 25 (41.6) 18 (40.9)
Data are presented as n (%) or mean ± SD.
*p < 0.05.
ANOVA ¼ analysis of variance; ICPI ¼ Interstitial Cystitis Problem Index;
ICSI ¼ Interstitial Cystitis Symptom Index; MBC ¼ maximal bladder capacity;
PUF ¼ pelvic pain and urinary/frequency; VAS ¼ visual analog scale.
Table 3
Comparison of patients negative for dyspareunia and those with pain in the vagina,






Age (y) 45.51 ± 12.9 45.43 ± 13.0 0.99
Symptom
duration
8.40 ± 7.8 7.89 ± 9.0 0.95
ICSI 13.03 ± 3.3 12.36 ± 3.8 0.65
ICPI 11.75 ± 2.9 11.15 ± 3.6 0.60
VAS-pain 4.56 ± 3.3 5.22 ± 2.6 0.58
VAS-urgency 6.38 ± 2.1 6.11 ± 2.3 0.84
PUF 18.18 ± 5.5 19.44 ± 5.7 0.57
MBC 654.25 ± 205.3 730.88 ± 172.9 0.15
Glomerulations
Grade 1 4 (6.6) 1 (2.4) 0.23
Grade 2 15 (25) 8 (19.5)
Grade 3 16 (26.6) 11 (26.8)
Grade 4 25 (41.6) 21 (51.2)
Data are presented as n (%) or mean ± SD.
* p < 0.05.
ANOVA ¼ analysis of variance; ICPI ¼ Interstitial Cystitis Problem Index;
ICSI ¼ Interstitial Cystitis Symptom Index; MBC ¼ maximal bladder capacity;
PUF ¼ pelvic pain and urinary/frequency; VAS ¼ visual analog scale.
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therapy, including pentosan polysulfate sodium therapy, intra-
vesical bladder therapy, or botulinum toxin A injection, was
suggested for the bladder. Speciﬁc treatment strategies for
pelvic ﬂoor muscle also included physical therapy and muscle
relaxants.
There are several limitations to this study. First, the analysis of
all conditions is based on self-reported questionnaires, although
they are all validated. Second, more severe cases (higher scores in
ICSI, ICPI, and PUF) were included. Third, the lack of information on
a previous history of abuse or psychological dysfunction, non-
bladder syndrome condition, and the possibility of vulvodynia and
endometriosis are covariates and associated with dyspareunia and
lower urinary tract symptoms.
5. Conclusion
IC/BPS women with dyspareunia have signiﬁcantly more severe
urological pain and a higher PUF scale score than women without
dyspareunia. Patients with dyspareunia radiated to the urinary
system (bladder) show more severe lower urinary tract symptoms
(urgency) and larger anesthetic MBC. Physicians should consider
sexual pain disorder in the management of patients with IC/BPS
and use the PUF scale to evaluate not only IC-speciﬁc lower urinary
tract symptoms but also sexual pain disorder.Conﬂicts of interest
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